Trenches in Transplant Surgery

Sabin Subedi
  • 5.0 (3)
  • Medicine
  • Updated Daily

Step into the forefront of abdominal transplant surgery — where innovation meets ongoing complexity. Machine perfusion and normothermic regional perfusion (NRP) are reshaping organ preservation and donor utilization, with growing evidence that these technologies improve graft assessment and early outcomes. Yet reviews continue to highlight key challenges — ischemia–reperfusion injury, biliary complications in DCD grafts, and the logistical demands of perfusion platforms. Despite these hurdles, transplantation is shifting from an urgent, unpredictable field toward a planned, daytime specialty. The next horizon, underscored by recent expert reviews, is true organ banking — bringing us closer to on-demand, schedulable transplantation. Disclaimer: This content was created by Sabin Subedi with the assistance of AI tools and is intended for educational purposes only. Views expressed are independent commentary on abdominal transplant surgery and should not be used in place of institutional protocols, clinical judgment, or individualized medical decision-making.

  1. 1d ago

    Edit the Disease - or Replace the Liver?

    Edit the Disease - or Replace the Liver? examines whether mRNA therapy, gene replacement, CRISPR and base editing could eventually prevent the need for liver transplantation. Human studies already show that therapeutic mRNA can temporarily replace missing hepatic enzymes, while gene editors can modify hepatocytes after intravenous delivery. Early BEAM-302 results in alpha-1 antitrypsin deficiency are particularly relevant: correcting the PiZ mutation may address both toxic protein accumulation in the liver and inadequate functional protein in the circulation. The central distinction is that correcting a molecular defect is not the same as restoring a damaged organ. Genetic medicine is most likely to replace transplantation in monogenic diseases treated before fibrosis, portal hypertension or multiorgan injury. It cannot currently reconstruct advanced cirrhotic architecture, rapidly replace lost hepatocyte mass in acute liver failure or reliably eliminate established liver cancer. Moderna’s personalized melanoma mRNA therapy offers a useful model for sequence-guided cancer treatment, but it is not a proven cure and has not been shown to replace transplantation for HCC. Meanwhile, machine perfusion could eventually allow donor livers to be genetically modified before implantation - transforming transplantation from organ preservation toward active organ repair. Bottom line: Genetic medicine may eliminate selected indications for liver transplantation before it eliminates transplantation itself. The decisive variable will be timing: correcting the disease before the liver becomes irreversibly damaged.

    Edit the Disease - or Replace the Liver?

  2. 3d ago

    Abdominal Organ Procurement as Advanced Surgical Training A Contemporary 12-Week Curriculum — 2026 Update

    This episode makes the case that abdominal organ procurement—especially DBD recovery—is one of the most underused training environments for major abdominal surgery. The central argument is that procurement should not be viewed simply as “organ removal.” A well-structured DBD recovery exposes trainees to the supraceliac and infrarenal aorta, IVC, renal hila, porta hepatis, celiac axis, SMA, mesenteric root, pancreas, and retroperitoneum in a single operation. That makes it a powerful platform for learning vascular control, complex anatomy, tissue handling, operative efficiency, and surgical judgment. The episode also updates this idea for the modern transplant era. A contemporary procurement surgeon must understand more than classical DBD technique: DCD workflows, NRP, hypothermic and normothermic machine perfusion, organ-quality assessment, preservation strategy, logistics, and coordination across thoracic, abdominal, OPO, anesthesia, and perfusion teams. A proposed 12-week immersive curriculum uses DBD procurement as the technical backbone. Trainees progress from observation and basic exposure to organ-specific liver, kidney, and pancreas recovery, then to DCD, NRP, machine perfusion, complication management, and ultimately supervised leadership of a complete multiorgan recovery. A major theme is that training should be competency-based rather than case-count based. The goal is not merely to attend a certain number of procurements, but to demonstrate reliable performance in anatomy, vascular control, organ stewardship, decision-making, teamwork, and leadership. The broader message is simple: Abdominal organ procurement can function as a concentrated fellowship in major abdominal anatomy. For residents, fellows, and even practicing surgeons, repeated DBD procurement can provide exposure to vascular and retroperitoneal maneuvers that might otherwise take years to accumulate through conventional general surgery alone.

    Abdominal Organ Procurement as Advanced Surgical Training A Contemporary 12-Week Curriculum — 2026 Update

  3. 3d ago

    Rethinking the Liver Donor Risk Index

    The Number on the Offer: Rethinking the Liver Donor Risk Index The liver donor risk index helped transplant teams quantify donor-associated graft risk. But an organ-offer decision requires more than a score: it depends on the recipient’s urgency and reserve, procurement findings, preservation and transport, operative complexity, and the consequences of continued waiting. This episode examines why weak predictive performance does not mean donor biology is irrelevant. Outcomes among transplanted livers already reflect clinical selection, matching, and management—and cannot establish that declined organs would have performed equally well. Modern preservation may change historical risk relationships, but it does not eliminate uncertainty. The practical takeaway: use LDRI as context, not an acceptance threshold. Identify the specific concern, explain its relevance to this candidate, document feasible mitigation, and compare accepting now with the realistic alternative of declining. The central question is not simply “How risky is this liver?” but “Does this liver offer this patient a better chance than waiting?” Evidence note: The cited September 2026 study and its reported AUC of 0.58 remain unverified pending the original paper or DOI.

    Rethinking the Liver Donor Risk Index

  4. Feb 22

    Lactate trends reveal organ transplant viability

    This episode explores the critical role of **lactate metabolism** as a biomarker for assessing organ quality in **Donation after Circulatory Death (DCD)** compared to **Donation after Brain Death (DBD)**. While the heart typically consumes lactate and the liver clears it, the **warm ischemia** inherent in DCD causes a shift toward anaerobic metabolism and significant lactate accumulation. To mitigate this injury, advanced **ex vivo perfusion** and **normothermic regional perfusion** techniques are utilized to monitor **lactate clearance trends** as a primary indicator of graft viability. While absolute thresholds exist, such as specific millimole targets for livers and hearts, the **downward trajectory** of lactate levels during perfusion is a more reliable predictor of post-transplant success. Clinical data suggest that when these metabolic markers are managed effectively, DCD organs can achieve **survival outcomes** comparable to traditional DBD grafts. Ultimately, the conversation highlights how **metabolic monitoring** transforms high-risk donor organs into viable options for transplantation.

    Lactate trends reveal organ transplant viability

  5. 10/30/2025

    The Future of Transplant (Organ Transplantation in 2050)

    By 2050, organ transplantation will be radically transformed—from a scarce, donor-dependent therapy into a diverse ecosystem of biological and technological solutions. Patients will receive organs from genetically engineered pigs, bioprinting labs, or even their own regenerated cells, while many others may avoid transplantation altogether through regenerative medicine, gene editing, and artificial organ implants. Advances in AI-driven allocation, precision medicine, and opt-out donation policies will expand access and efficiency, though disparities may persist between rich and poor regions. As bioengineered and artificial organs blur the boundaries between human, animal, and machine, the ethical, psychological, and cultural dimensions of identity, equity, and mortality will become central. Ultimately, the future of end-stage organ disease lies not only in replacing organs but in redefining what it means to heal, live, and thrive beyond biological limits.

    The Future of Transplant (Organ Transplantation in 2050)

  6. 10/07/2025

    Regulatory T Cells in Organ Transplantation

    Regulatory T cells (Tregs)—discovered by Shimon Sakaguchi, Mary Brunkow, and Fred Ramsdell, who were awarded the 2025 Nobel Prize—are central to inducing immune tolerance and preventing organ transplant rejection. These CD4⁺FoxP3⁺ cells suppress alloimmune responses through multiple mechanisms (IL-10, TGF-β secretion; CTLA-4–mediated dendritic cell modulation; IL-2 consumption; cytotoxic effects on effector T cells). Clinically, higher Treg levels correlate with better graft survival and fewer rejection episodes. Early-phase trials in kidney and liver transplantation show that adoptive Treg infusions are safe, reduce acute rejection, and allow lowering of toxic immunosuppressive drugs. Approaches include polyclonal Tregs, donor-specific Tregs (darTregs), low-dose IL-2 to expand Tregs in vivo, and cutting-edge CAR-engineered Tregs for precise graft targeting. Key challenges remain—maintaining Treg stability and specificity, avoiding off-target immunosuppression, and overcoming complex cell manufacturing. Future directions focus on CAR/FOXP3-engineered “super Tregs,” orthogonal IL-2 systems for selective in vivo expansion, biomaterial-based delivery, and scalable Treg production from thymus or iPSCs. These advances aim to achieve durable, donor-specific tolerance with minimal lifelong immunosuppression—potentially transforming transplant care.

    Regulatory T Cells in Organ Transplantation

  7. 10/03/2025

    Desensitization and Pheresis in Kidney Transplant

    Desensitization has transformed kidney transplantation for patients with high immunologic risk by lowering or removing antibodies that would otherwise cause graft loss. Pre- and peri-transplant plasmapheresis (therapeutic plasma exchange) with low-dose intravenous immunoglobulin (IVIG), sometimes combined with B-cell depletion (rituximab) or newer agents (imlifidase, bortezomib, daratumumab), is standard for HLA- or ABO-incompatible living and deceased donor transplants. Plasmapheresis is also first-line therapy for antibody-mediated rejection and for recurrent focal segmental glomerulosclerosis (FSGS), where early, intensive sessions can induce remission; resistant cases may benefit from lipoprotein apheresis. Highly sensitized patients are identified by elevated panel reactive antibody (PRA/cPRA) levels; allocation systems now prioritize these candidates, but desensitization remains key when compatible organs are unavailable. Pediatric protocols aim to minimize apheresis burden while maintaining good graft survival. In parallel, xenotransplantation—especially gene-edited pig kidneys—is entering early human trials; here, preemptive or rescue plasmapheresis/IVIG has shown utility in controlling anti-pig antibody responses. Emerging strategies target long-lived plasma cells, complement pathways, and precise antibody monitoring to make incompatible and xenogeneic transplantation safer and more durable.

    Desensitization and Pheresis in Kidney Transplant

  8. 10/02/2025

    Organ Offer Review - Kidney and Liver Transplant

    When a deceased-donor offer arrives, the on-call surgeon rapidly weighs donor organ quality, recipient need, and logistics within OPTN/UNOS policy. For kidneys, decisions hinge on KDPI, creatinine/AKI course, machine-pump metrics, procurement biopsy (e.g., glomerulosclerosis/arteriosclerosis), HLA antibodies/virtual or physical crossmatch, and the patient’s wait time/sensitization; kidneys tolerate longer cold ischemia and can be deferred a few hours if needed. For livers, the focus is MELD/urgency, donor stability (pressors/arrest), DCD status and warm ischemia, steatosis by appearance/biopsy, extreme transaminases, size match, and the ability to transplant quickly (short cold time ± normothermic perfusion), with far less emphasis on HLA. Logistics—distance/transport mode, OR and team readiness, projected cold ischemia, and availability of perfusion—can tip the balance for either organ. Donor infections (e.g., HCV NAT+) are acceptable with informed consent and modern antivirals; ABO compatibility is mandatory (liver ABO-incompatible only in rare emergencies). UNOS DonorNet, offer filters, image/biopsy sharing, and emerging AI triage tools streamline evaluation, while center-specific protocols and national metrics encourage timely, appropriate acceptance rather than reflexive decline. Ethically, surgeons balance utility and equity—accepting enough risk to save the right patient now without wasting scarce grafts—recognizing that kidney transplantation is comparatively elective in timing, whereas liver transplantation is often urgent and less forgiving of delay.

    Organ Offer Review - Kidney and Liver Transplant
See All (49)

Ratings & Reviews

5
out of 5
3 Ratings

About

Step into the forefront of abdominal transplant surgery — where innovation meets ongoing complexity. Machine perfusion and normothermic regional perfusion (NRP) are reshaping organ preservation and donor utilization, with growing evidence that these technologies improve graft assessment and early outcomes. Yet reviews continue to highlight key challenges — ischemia–reperfusion injury, biliary complications in DCD grafts, and the logistical demands of perfusion platforms. Despite these hurdles, transplantation is shifting from an urgent, unpredictable field toward a planned, daytime specialty. The next horizon, underscored by recent expert reviews, is true organ banking — bringing us closer to on-demand, schedulable transplantation. Disclaimer: This content was created by Sabin Subedi with the assistance of AI tools and is intended for educational purposes only. Views expressed are independent commentary on abdominal transplant surgery and should not be used in place of institutional protocols, clinical judgment, or individualized medical decision-making.

Information